8BSN image
Entry Detail
PDB ID:
8BSN
Keywords:
Title:
Human GLS in complex with compound 27
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2022-11-25
Release Date:
2023-01-18
Method Details:
Experimental Method:
Resolution:
2.49 Å
R-Value Free:
0.21
R-Value Work:
0.20
R-Value Observed:
0.20
Space Group:
I 41 2 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Glutaminase kidney isoform, mitochondrial 65 kDa chain
Chain IDs:A
Chain Length:315
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.
J Med Chem 62 6540 6560 (2019)
PMID: 31199640 DOI: 10.1021/acs.jmedchem.9b00260

Abstact

Tumors have evolved a variety of methods to reprogram conventional metabolic pathways to favor their own nutritional needs, including glutaminolysis, the first step of which is the hydrolysis of glutamine to glutamate by the amidohydrolase glutaminase 1 (GLS1). A GLS1 inhibitor could potentially target certain cancers by blocking the tumor cell's ability to produce glutamine-derived nutrients. Starting from the known GLS1 inhibitor bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide, we describe the medicinal chemistry evolution of a series from lipophilic inhibitors with suboptimal physicochemical and pharmacokinetic properties to cell potent examples with reduced molecular weight and lipophilicity, leading to compounds with greatly improved oral exposure that demonstrate in vivo target engagement accompanied by activity in relevant disease models.

Legend

Protein

Chemical

Disease

Primary Citation of related structures